Uveal Melanoma & Brachytheraphy: Long-term Outcomes.

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04364230` - Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)	Phase 1/Phase 2
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Active, not recruiting	`NCT05542342` - Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.	Phase 2
Completed	`NCT02849145` - Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)	N/A
Recruiting	`NCT01438658` - Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma	N/A
Not yet recruiting	`NCT00811200` - Treatment Of Radiation Retinopathy Trial	Phase 2/Phase 3
Completed	`NCT00121225` - Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma	Phase 2
Recruiting	`NCT05077280` - A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma	Phase 2
Completed	`NCT03297424` - A Study of PLX2853 in Advanced Malignancies.	Phase 1
Withdrawn	`NCT05482074` - Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2	Phase 2
Completed	`NCT04551352` - A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas	Phase 1
Not yet recruiting	`NCT06246149` - Adjuvant Tebentafusp in High Risk Ocular Melanoma	Phase 3
Completed	`NCT01955941` - Vascular Response to Brachytherapy Using Functional OCT
Completed	`NCT00661622` - Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF	Phase 2
Recruiting	`NCT05502900` - Adjuvant Melatonin for Uveal Melanoma	Phase 3
Active, not recruiting	`NCT03070392` - Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma	Phase 2
Recruiting	`NCT06284512` - Uveal Melanoma - Comparative Study
Recruiting	`NCT05524935` - Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma	Phase 2
Active, not recruiting	`NCT02913417` - Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases	Phase 1/Phase 2
Not yet recruiting	`NCT06073548` - Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study

NCT number	NCT04577742
Study type	Observational
Source	Federico II University
Contact
Status	Completed
Phase
Start date	February 1, 2011
Completion date	March 30, 2020

Uveal Melanoma and Brachytheraphy: Long-term Outcomes.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms